IO Biotech 1.69$
Seite 1 von 1 Neuester Beitrag: 18.05.24 16:45 | ||||
Eröffnet am: | 14.06.23 18:10 | von: Vassago | Anzahl Beiträge: | 6 |
Neuester Beitrag: | 18.05.24 16:45 | von: Vassago | Leser gesamt: | 2.717 |
Forum: | Börse | Leser heute: | 1 | |
Bewertet mit: | ||||
Zahlen für Q1/23
- keine Umsätze
- Verlust 17 Mio. $
- Cash 129 Mio. $
- MK 49 Mio. $
- support operations through the third quarter of 2024
https://investors.iobiotech.com/news-events/news/...ults/default.aspx
Zahlen für Q2/23
- keine Umsätze
- Verlust 21 Mio. $
- Cash 110 Mio. $
- MK 107 Mio. $
- $75 million private placement
- expected to support operations into the fourth quarter of 2025
https://iobiotech.com/press-releases/...8-fe15-4ae2-aa0d-a198f9cf8d8e
https://investors.iobiotech.com/news-events/news/...pean/default.aspx
Zahlen für Q3/23
- keine Umsätze
- Verlust 22 Mio. $
- Cash 166 Mio. $
- MK 62 Mio. $
https://investors.iobiotech.com/news-events/news/...ults/default.aspx
Zahlen für Q1/24
- keine Umsätze
- Verlust 19 Mio. $
- Cash 118 Mio. $
- MK 91 Mio. $
- Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endpoint of progression free survival (PFS) is now projected to occur in first half of 2025
- expected cash runway into the fourth quarter of 2025
https://investors.iobiotech.com/news-events/news/...ghts/default.aspx